NK cells in human disease: An evolving story

Clinical Immunology

Volumn 143, Issue 3, 2012, Pages 203-206

  Guerini, Franca R ^a   Clerici, Mario ^a,b  

^a IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA B ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ALLELE; ANTIGEN EXPRESSION; CELL ACTIVITY; DISEASE PREDISPOSITION; DISEASES; EDITORIAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NATURAL KILLER CELL; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION;

FEMALE; HIV INFECTIONS; HLA-B ANTIGENS; HLA-C ANTIGENS; HUMANS; KILLER CELLS, NATURAL; RECEPTORS, KIR;

EID: 84861228329     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2012.03.003     Document Type: Editorial

References (40)

1. Winter C.C., Gumperz J.E., Parham P., Long E.O., Wagtmann N. Direct binding and functional transfer of NK cell inhibitory receptors reveal novel patterns of HLA-C allotype recognition. J. Immunol. 1998, 161:571-577.
2. Ahlenstiel G., Martin M.P., Gao X., Carrington M., Rehermann B. Distinct KIR/HLA compound genotypes affect the kinetics of human antiviral natural killer cell responses. J. Clin. Invest. 2008, 118:1017-1026.
3. Gardiner C.M., Guethlein L.A., Shilling H.G., Pando M., Carr W.H., Rajalingam R., Vilches C., Parham P. Different NK cell surface phenotypes defined by the DX9 antibody are due to KIR3DL1 gene polymorphism. J. Immunol. 2001, 166:2992-3001.
4. Yawata M., Yawata N., Draghi M., Little A.M., Partheniou F., Parham P. Roles for HLA and KIR polymorphisms in natural killer cell repertoire selection and modulation of effector function. J. Exp. Med. 2006, 203:633-645.
5. Khakoo S.I., Carrington M. KIR and disease: a model system or system of models?. Immunol. Rev. 2006, 214:186-201.
6. Parham P. MHC class I molecules and KIRs in human history, health and survival. Nat. Rev. Immunol. 2005, 5:201-214.
7. De Maria A., Moretta L. NK cell function in HIV-1 infection. Curr. HIV Res. 2008, 6:433-440. (Review).
8. Kulkarni S., Martin M.P., Carrington M. The yin and yang of HLA and KIR in human disease. Semin. Immunol. 2008, 20:343-352.
9. Kamya P., Tallon B., Melendez-Pena C., Parsons M.S., Migueles S.A., Connors M., Miconiatis S., Song R., Boulet S., Bruneau J., Tremblay C.L., Bernard N.F. Inhibitory Killer Immunoglobulin-like receptors to self HLA-B and HLA-C ligands contribute differentially to Natural Killer cell functional potential in HIV infected Slow Progressors. Clin Immunol. 2012, 143:246-255.
10. Kim S., Poursine-Laurent J., Truscott S.M., Lybarger L., Song Y.J., Yang L., French A.R., Sunwoo J.B., Lemieux S., Hansen T.H., Yokoyama W.M. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 2005, 436:709-713.
11. Anfossi N., Andre P., Guia S., Falk C.S., Roetynck S., Stewart C.A., Stewart C.A., Breso V., Frassati C., Reviron D., Middleton D., Romagné F., Ugolini S., Vivier E. Human NK cell education by inhibitory receptors for MHC class I. Immunity 2006, 25:331-342.
12. Kim S., Sunwoo J.B., Yang L., Choi T., Song Y.J., French A.R., Vlahiotis A., Piccirillo J.F., Cella M., Colonna M., Mohanakumar T., Hsu K.C., Dupont B., Yokoyama W.M. HLA alleles determine differences in human natural killer cell responsiveness and potency. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:3053-3058.
13. Cooley S., Xiao F., Pitt M., Gleason M., McCullar V., Bergemann T.L., McQueen K.L., Guethlein L.A., Parham P., Miller J.S. A subpopulation of human peripheral blood NK cells that lacks inhibitory receptors for self-MHC is developmentally immature. Blood 2007, 110:578-586.
14. De Maria A., Moretta L. HLA-class I-specific inhibitory receptors in HIV-1 infection. Hum. Immunol. 2000, 61:74-81. (Review).
15. Jennes W., Verheyden S., Demanet C., Adjé-Touré C.A., Vuylsteke B., Nkengasong J.N., Kestens L. Cutting edge: resistance to HIV-1 infection among African female sex workers is associated with inhibitory KIR in the absence of their HLA ligands. J. Immunol. 2006, 177:6588-6592.
16. Ravet S., Scott-Algara D., Bonnet E., Tran H.K., Tran T., Nguyen N., Truong L.X., Theodorou I., Barré-Sinoussi F., Pancino G., Paul P. Distinctive NK-cell receptor repertoires sustain high-level constitutive NK-cell activation in HIV-exposed uninfected individuals. Blood 2007, 109:4296-4305.
17. Long B.R., Ndhlovu L.C., Oksenberg J.R., Lanier L.L., Hecht F.M., Nixon D.F., Barbour J.D. Conferral of enhanced natural killer cell function by KIR3DS1 in early human immunodeficiency virus type 1 infection. J. Virol. 2008, 82:4785-4792.
18. Guerini F.R., Lo Caputo S., Gori A., Bandera A., Mazzotta F., Uglietti A., Zanzottera M., Maserati R., Clerici M. Under representation of the inhibitory KIR3DL1 molecule and the KIR3DL1+/BW4+ complex in HIV exposed seronegative individuals. J. Infect. Dis. 2011, 203:1235-1239.
19. Boulet S., Sharafi S., Simic N., Bruneau J., Routy J.P., Tsoukas C.M., Bernard N.F. Increased proportion of KIR3DS1 homozygotes in HIV-exposed uninfected individuals. AIDS 2008, 22:595-599.
20. Parsons M.S., Boulet S., Song R., Bruneau J., Shoukry N.H., Routy J.P., Tsoukas C.M., Bernard N.F. Mind the gap: lack of association between KIR3DL1*004/HLA-Bw4-induced natural killer cell function and protection from HIV infection. J. Infect. Dis. 2010, 202(Suppl. 3):S356-S360.
21. Boulet S., Song R., Kamya P., Bruneau J., Shoukry N.H., Tsoukas C.M., Bernard N.F. HIV protective KIR3DL1 and HLA-B genotypes influence NK cell function following stimulation with HLA-devoid cells. J. Immunol. 2010, 184:2057-2064.
22. Eller M.A., Koehler R.N., Kijak G.H., Eller L.A., Guwatudde D., Marovich M.A., Michael N.L., de Souza M.S., Wabwire-Mangen F., Robb M.L., Currier J.R., Sandberg J.K. Human immunodeficiency virus type 1 infection is associated with increased NK cell polyfunctionality and higher levels of KIR3DL1+ NK cells in ugandans carrying the HLA-B Bw4 motif. J. Virol. 2011, 85:4802-4811.
23. Tiemessen C.T., Paximadis M., Minevich G., Winchester R., Shalekoff S., Gray G.E., Sherman G.G., Coovadia A.H., Kuhn L. Natural killer cell responses to HIV-1 peptides are associated with more activating KIR genes and HLA-C genes of the C1 allotype. J. Acquir. Immune Defic. Syndr. 2011, 57:181-189.
24. Paximadis M., Minevich G., Winchester R., Schramm D.B., Gray G.E., Sherman G.G., Coovadia A.H., Kuhn L., Tiemessen C.T. KIR-HLA and maternal-infant HIV-1 transmission in sub-Saharan Africa. PLoS one 2011, 6:e16541.
25. Ballan W.M., Vu B.A., Long B.R., Loo C.P., Michaëlsson J., Barbour J.D., Lanier L.L., Wiznia A.A., Abadi J., Fennelly G.J., Rosenberg M.G., Nixon D.F. Natural killer cells in perinatally HIV-1-infected children exhibit less degranulation compared to HIV-1-exposed uninfected children and their expression of KIR2DL3, NKG2C, and NKp46 correlates with disease severity. J. Immunol. 2007, 179:3362-3370.
26. Martin M.P., Gao X., Lee J.H., Nelson G.W., Detels R., Goedert J.J., Buchbinder S., Hoots K., Vlahov D., Trowsdale J., Wilson M., O'Brien S.J., Carrington M. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat. Genet. 2002, 4:429-434.
27. Alter G., Rihn S., Walter K., Nolting A., Martin M., Rosenberg E.S., Miller J.S., Carrington M., Altfeld M. HLA class I subtype-dependent expansion of KIR3DS1+ and KIR3DL1+ NK cells during acute human immunodeficiency virus type 1 infection. J. Virol. 2009, 83:6798-6805.
28. Pelak K., Need A.C., Fellay J., Shianna K.V., Feng S., Urban T.J., Ge D., De Luca A., Martinez-Picado J., Wolinsky S.M., Martinson J.J., Jamieson B.D., Bream J.H., Martin M.P., Borrow P., Letvin N.L., McMichael A.J., Haynes B.F., Telenti A., Carrington M., Goldstein D.B., Alter G. NIAID Center for HIV/AIDS Vaccine Immunology. Copy number variation of KIR genes influences HIV-1 control. PLoS Biol. 2011, 9:e1001208.
29. Long B.R., Erickson A.E., Chapman J.M., Barbour J.D., Vu B.A., Ho E.L., Lanier L.L., Sauer M.M., Carvalho K.I., Nixon D.F., Kallas E.G. Increased number and function of natural killer cells in human immunodeficiency virus 1-positive subjects co-infected with herpes simplex virus 2. Immunology 2010, 129:186-196.
30. Qi Y., Martin M.P., Gao X., Jacobson L., Goedert J.J., Buchbinder S., Kirk G.D., O'Brien S.J., Trowsdale J., Carrington M. KIR/HLA pleiotropism: protection against both HIV and opportunistic infections. PLoS Pathog. 2006, 8:e79.
31. Gaudieri S., DeSantis D., McKinnon E., Moore C., Nolan D., Witt C.S., Mallal S.A., Christiansen F.T. Killer immunoglobulin-like receptors and HLA act both independently and synergistically to modify HIV disease progression. Genes Immun. 2005, 6:683-690.
32. Wong A.H., Williams K., Reddy S., Wilson D., Giddy J., Alter G., Ghebremichael M., Carrington M.N., Ndung'u T., Walker B.D., Altfeld M., Carr W.H. Alterations in natural killer cell receptor profiles during HIV type 1 disease progression among chronically infected South African adults. AIDS Res. Hum. Retroviruses 2010, 26:459-469.
33. Martin M.P., Qi Y., Gao X., Yamada E., Martin J.N., Pereyra F., Colombo S., Brown E.E., Shupert W.L., Phair J., Goedert J.J., Buchbinder S., Kirk G.D., Telenti A., Connors M., O'Brien S.J., Walker B.D., Parham P., Deeks S.G., McVicar D.W., Carrington M. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat. Genet. 2007, 39:733-740.
34. Kamya P., Boulet S., Tsoukas C.M., Routy J.P., Thomas R., Côté P., Boulassel M.R., Baril J.G., Kovacs C., Migueles S.A., Connors M., Suscovich T.J., Brander C., Tremblay C.L., Bernard N. Canadian cohort of HIV infected slow progressors. Receptor-ligand requirements for increased NK cell polyfunctional potential in slow progressors infected with HIV-1 coexpressing KIR3DL1*h/*y and HLA-B*57. J. Virol. 2011, 85:5949-5960.
35. Soria A., Guerini F.R., Bandera A., Bolognesi E., Uglietti A., Fusco C., Zucchi P., Maserati R., Rizzardini G., Clerici M., Gori A. KIR-HLA genotypes in HIV-infected patients lacking immunological recovery despite effective antiretroviral therapy. PloS one 2011, e27349. 10.1371/journal.pone.0027349.
36. Merino A., Malhotra R., Morton M., Mulenga J., Allen S., Hunter E., Tang J., Kaslow R.A. Impact of a functional KIR2DS4 allele on heterosexual HIV-1 transmission among discordant Zambian couples. J. Infect. Dis. 2011, 203:487-495.
37. Guerini F.R., Mancuso R., Agostini S., Agliardi C., Zanzottera M., Hernis A., Tourlaki A., Calvo M.G., Bellinvia M., Brambilla L., Clerici M. Activating KIR/HLA Complexes In Classic Kaposi's Sarcoma. Infect. Agent. Cancer 2012, 7:9. 10.1186/1750-9378-7-9.
38. Lorentzen A.R., Karlsen T.H., Olsson M., Smestad C., Mero I.L., Woldseth B., Sun J.Y., Senitzer D., Celius E.G., Thorsby E., Spurkland A., Lie B.A., Harbo H.F. Killer immunoglobulin-like receptor ligand HLA-Bw4 protects against multiple sclerosis. Ann. Neurol. 2009, 65:658-666.
39. Fusco C., Guerini F.R., Nocera G., Ventrella G., Caputo D., Valentino M., Agliardi C., Gallotti J., Brescia Morra V., Florio C., Clerici M., Lombardi M.L. KIRs and their HLA-ligands in remitting-relapsing multiple sclerosis. J. Neuroimmunol. 2010, 229:232-237.
40. Jelcic I., Hsu K.C., Kakalacheva K., Breiden P., Dupont B., Uhrberg M., Martin R., Münz C., Lünemann J.D. Killer immunoglobulin-like receptor locus polymorphisms in multiple sclerosis. Mult. Scler. 2011, 1-8. 10.1177/1352458511431726.